Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Jun 30;46(3):394-8.
doi: 10.3349/ymj.2005.46.3.394.

Pretreatment with ursodeoxycholic acid (UDCA) as a novel pharmacological intervention in hepatobiliary scintigraphy

Hwan Jeong Jeong  1 , Chang Guhn Kim
Affiliations
Clinical Trial

Pretreatment with ursodeoxycholic acid (UDCA) as a novel pharmacological intervention in hepatobiliary scintigraphy

Hwan Jeong Jeong et al. Yonsei Med J. .

Abstract

The purpose of this volunteer study was to investigate whether pretreatment with UDCA before the administration of (99m)Tc DISIDA affects the biliary excretion of the DISIDA, and whether it can shorten the total imaging time. Ten young, healthy volunteers (eight males, two females, mean age: 26.3 +/- 2.1 years) participated in the study. Hepatobiliary scintigraphies were performed twice per volunteer within three days, for the control and the UDCA-pretreated studies. In the control study, the gallbladder (GB) was observed first in four cases and the intestine was observed first in another four cases; in contrast, in the UDCA challenge study, the GB was observed first in eight cases. The quantitative results for the factors related to the GB differed significantly between the control and challenge studies. When the subjects were pretreated with UDCA, the time duration until visualization of the GB was shortened, and the maximum activity of the GB became more intense. In conclusion, UDCA pretreatment before hepatobiliary scintigraphy can shorten the total imaging time for evaluating functional obstructions of the cystic duct and increase the specificity of the process.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hepatobiliary scintigraphies of a volunteer untreated with UDCA (A) and pretreated with UDCA (B). After pretreatment with UDCA, the GB (arrow) is visualized first, then the intestine.
Fig. 2
Fig. 2
Comparison of the time to visualization of the GB. The observation times of the GB converged without significant individual differences in eight cases of the UDCA pretreated hepatobiliary scintigraphies.
Fig. 3
Fig. 3
Hepatobiliary scintigraphies from a volunteer with untreated UDCA (A) and pretreated UDCA (B). After pretreatment with UDCA, the maximum activity of the GB is more intense than that in the control study.
See this image and copyright information in PMC

References

    1. Shea JA, Berlin JA, Escarce JJ, Clarke JR, Kinosian BP, Cabana MD, et al. Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med. 1994;154:2573–2581. - PubMed
    1. Choy D, Shi EC, McLean RG, Hoschl R, Murray IP, Ham JM. Cholescintigraphy in acute cholecystitis: use of intravenous morphine. Radiology. 1984;151:203–207. - PubMed
    1. Fink-Bennett D. Augmented cholescintigraphy: its role in detecting acute and chronic disorders of the hepatobiliary tree. Semin Nucl Med. 1991;21:128–139. - PubMed
    1. Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep. 2002;4:37–44. - PubMed
    1. Van de Meeberg PC, van Erpecum KJ, van Berge-Henegouwen GP. Therapy with ursodeoxycholic acid in cholestatic liver disease. Scand J Gastroenterol Suppl. 1993;200:15–20. - PubMed

Publication types